10:33 AM EDT, 09/29/2025 (MT Newswires) -- VolitionRx ( VNRX ) said Monday it has entered into an agreement with Hologic ( HOLX ) Diagenode for the co-marketing of Volition's Nu.Q Discover service, which provides drug developers and scientists with a range of assays for rapid epigenetic profiling.

Under the agreement, Hologic ( HOLX ) will co-market the service to its customers for an initial one-year term, with the potential to become an exclusive provider of the service, Volition said.